Evidence map›Paper›PMID 40725128›Full record

ReviewInternational journal of molecular sciences2025

Understanding the Pre-Clinical Stages of Parkinson's Disease: Where Are We in Clinical and Research Settings?

Camilla Dalla Verde, Sri Jayanti, Korri El Khobar, John A Stanford, Claudio Tiribelli, Silvia Gazzin

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Camilla Dalla VerdeLiver Brain Unit "Rita Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.ORCID 0009-0009-3678-8331
Sri JayantiEijkman Research Centre for Molecular Biology, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, Indonesia.
Korri El KhobarEijkman Research Centre for Molecular Biology, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, Indonesia.
John A StanfordDepartment of Cell Biology and Physiology, University of Kansas School of Medicine, Kansas City, KS 66160, USA.ORCID 0000-0002-4667-4057
Claudio TiribelliLiver Brain Unit "Rita Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.ORCID 0000-0001-6596-7595
Silvia GazzinLiver Brain Unit "Rita Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.ORCID 0000-0001-9403-3564

Funding

NIH for JAS; an internal grant of Fondazione Italiana Fegato - Onlus (Italian Liver Foundation-NPO) for CDV, CT, SG; Manajemen Talenta, the National Research and Innovation Agency of Indonesia for SJ; KEK has received no specific founding for this work P20GM103418 for JAS
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder in the world. PD is characterized by motor and non-motor symptoms, but the diagnosis primarily relies on the clinical assessment of postural and movement abnormalities, supported by imaging and genetic testing. It is widely accepted that the disease process begins decades before the onset of overt symptoms. Emerging evidence suggests that neuroinflammation plays a central role in the pathogenesis of PD, particularly during the pre-clinical phase. Activated microglia, increased levels of pro-inflammatory cytokines, and persistent oxidative stress have all been associated with the gradual loss of dopaminergic neurons. Although earlier detection and diagnosis remain elusive, achieving these goals is crucial for advancing prevention and disease-modifying strategies. Clinical studies are ongoing. To fill the gap, research models that recapitulate the chronic disease progression of PD are crucial to test preventive and disease-modifying strategies. This review briefly summarizes clinical knowledge on PD as a starting point for improving research models. Furthermore, we will critically evaluate how the existing models have been utilized and highlight opportunities to overcome their limitations and enhance the translational relevance to clinical application.

Indexed as

Parkinson DiseaseAnimalsCytokinesDisease Models, AnimalDisease ProgressionDopaminergic NeuronsHumansMicrogliaOxidative StressCytokinesBraakdisease-modifying strategiesinflammationmodelspre-clinicalpreventionredox-stressvagusα-synuclein

Identifiers

PMID40725128
PMCPMC12295964

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.